Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic

Article activity feed

1. Version published to 10.1093/infdis/jiab142

   Mar 16, 2021
2. 

   ScreenIT

   Feb 15, 2021

   SciScore for 10.1101/2021.02.12.430933: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	Consent: Donors signed informed consent and agreed to additional testing.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Measurement of SARS-CoV-2 and HCoV-229E neutralizing antibodies: SARS-CoV-2 and HCoV-229E neutralizing antibody (nAb) titers were determined using materials and methods previously reported [1].	HCoV-229E neutralizing antibody suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Briefly, 2-fold serially diluted samples were incubated with equal volumes of SARS-CoV-2 (strain …

   SciScore for 10.1101/2021.02.12.430933: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	Consent: Donors signed informed consent and agreed to additional testing.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Measurement of SARS-CoV-2 and HCoV-229E neutralizing antibodies: SARS-CoV-2 and HCoV-229E neutralizing antibody (nAb) titers were determined using materials and methods previously reported [1].	HCoV-229E neutralizing antibody suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Briefly, 2-fold serially diluted samples were incubated with equal volumes of SARS-CoV-2 (strain “BavPat1/2020”, Charité Berlin, Germany) or HCoV-229E (for IVIG samples, Cat. no. VR-740, ATCC, Rockville, MD) at 103.0 tissue culture infectious doses 50% per milliliter (TCID50/ml) and incubated for 150 min before titration on Vero cells (for SARS-CoV-2; Cat. no. 84113001, ECACC, Porton Down, Salisbury, UK) or MRC-5 cells (for HCoV-229E; Cat. no. CCL-171, ATCC) in eight-fold replicates per dilution.	Vero suggested: None MRC-5 suggested: None
   Software and Algorithms
   Sentences	Resources
   COVID-19 convalescent plasma samples: 438 COVID-19 CP samples collected between March and July 2020 were obtained from Austrian (n = 300) and US (n = 138) plasma donation centers (BioLife).	BioLife suggested: None
   Data analysis and visualization was done using GraphPad Prism v8.1.1 (San Diego, CA), R Studio v1.1.383 (Boston, MA), Minitab v. 17.3.1 (State College, PA) and Microsoft Excel.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798) Minitab suggested: (Minitab, RRID:SCR_014483) Microsoft Excel suggested: (Microsoft Excel, RRID:SCR_016137)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.02.12.430933v1 on bioRxiv

   Feb 12, 2021